RC方案治疗复发/难治套细胞淋巴瘤的临床效果(4)
[11] SPURGEON S E， PINDYCK T， OKADA C， et al. Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma[J]. Leukemia & Lymphoma， 2011，52(8)：1488-1494.
[12] INWARDS D J， FISHKIN P A， HILLMAN D W， et al. Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group[J]. Cancer， 2008，113(1)：108-116.
[13] NAGAI H， OGURA M， KUSUMOTO S， et al. Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma[J]. European Journal of Haematology， 2011，86(2)：117-123.
[14] SEYMOUR J F， KURZROCK R， FREIREICH E J， et al. 2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia[J]. Blood， 1994，83(10)：2906-2911.
[15] 杜雅慧，王文，紀春岩. 克拉屈滨的临床应用[J]. 中国处方药， 2013，11(3)：33-35.
(本文编辑 马伟平), 百拇医药(王亚文 薛宏伟)
[12] INWARDS D J， FISHKIN P A， HILLMAN D W， et al. Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group[J]. Cancer， 2008，113(1)：108-116.
[13] NAGAI H， OGURA M， KUSUMOTO S， et al. Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma[J]. European Journal of Haematology， 2011，86(2)：117-123.
[14] SEYMOUR J F， KURZROCK R， FREIREICH E J， et al. 2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia[J]. Blood， 1994，83(10)：2906-2911.
[15] 杜雅慧，王文，紀春岩. 克拉屈滨的临床应用[J]. 中国处方药， 2013，11(3)：33-35.
(本文编辑 马伟平), 百拇医药(王亚文 薛宏伟)